PI
SNDX icon

Putnam Investments’s Syndax Pharmaceuticals SNDX Stock Holding History

Putnam Investments’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-205,040
Closed -$3.52M – 827
2021
Q2 		$3.52M Hold
205,040
– – 0.01% 616
2021
Q1 		$4.58M Buy
+205,040
New +$4.63M 0.01% 516

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Putnam Investments's SNDX Position: Q3 2021 in Review

Putnam Investments sold out of Syndax Pharmaceuticals (SNDX) in Q3 2021, closing a stake of 205,040 shares — an estimated $3.52M sold.

Putnam Investments first reported a position in SNDX in Q1 2021 and held it in 2 quarters. The position peaked at $4.58M in Q1 2021. 123 funds tracked by Wall St. Rank hold SNDX as of Q3 2021.

  • Putnam Investments reported no remaining Syndax Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Putnam Investments sold 205,040 Syndax Pharmaceuticals shares in Q3 2021, an estimated $3.52M.
  • Putnam Investments first reported a position in Syndax Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Putnam Investments's Syndax Pharmaceuticals position peaked at $4.58M in Q1 2021.
  • 123 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2021.

Based on Putnam Investments's 13F filing for Q3 2021, filed 15 Nov 2021.